Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Other Accumulated Expenses (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of Other Accumulated Expenses data on record, last reported at $2.8 million in Q4 2025.

  • For Q4 2025, Other Accumulated Expenses rose 352.05% year-over-year to $2.8 million; the TTM value through Dec 2025 reached $2.8 million, up 352.05%, while the annual FY2025 figure was $2.8 million, 352.05% up from the prior year.
  • Other Accumulated Expenses reached $2.8 million in Q4 2025 per ACRS's latest filing, up from $2.7 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $2.8 million in Q4 2025 and bottomed at $217000.0 in Q4 2022.
  • Average Other Accumulated Expenses over 5 years is $1.4 million, with a median of $733000.0 recorded in 2022.
  • Peak YoY movement for Other Accumulated Expenses: crashed 87.49% in 2022, then surged 568.7% in 2025.
  • A 5-year view of Other Accumulated Expenses shows it stood at $1.7 million in 2021, then plummeted by 87.49% to $217000.0 in 2022, then surged by 31.34% to $285000.0 in 2023, then soared by 113.68% to $609000.0 in 2024, then surged by 352.05% to $2.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Accumulated Expenses were $2.8 million in Q4 2025, $2.7 million in Q3 2025, and $2.7 million in Q2 2025.